Introduction {#sec1-1}
============

Breast cancer is now widely recognized that is a heterogeneous disease composed of different subtypes, characterized by their different clinico-pathological features, prognoses and responses to treatment (Perou et al., 2000; Sorlie et al., 2001). Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. This molecular subtype is particularly aggressive, frequently seen in premenopausal women, and accounts for 10--15% of breast cancers in white women, with a higher prevalence among black women (Perou et al.,1999; Rais et al., 2012).

Obesity is associated with poorer outcomes in patients with hormone receptor-positive breast cancer, but this association is not well established for triple-negative breast cancer. Therefore, we retrospectively investigated the effects of BMI at the time of breast cancer diagnosis on outcomes in triple-negative breast cancer.

Materials and Methods {#sec1-2}
=====================

This descriptive and analytical retrospective cohort study included all female patients with triple-negative breast cancer who received treatment at the Regional Oncology Center Hassan II-Oujda, Morocco, between January 2009 and December 2011. Exclusion criteria included ER or PR positivity, HER2 overexpression/ amplification and male sex.

Information was available for all patients' age and menopausal status at diagnosis, height and weight at diagnosis (for BMI calculations), tumor size, number of lymph nodes removed, number of positive lymph nodes, histological type and grade, treatment regimen.

Associations between BMI and other characteristics were analyzed using the chi-square test. For the assessment of the influence of BMI on survival outcome (OS and DFS at 5 years), we adjusted for age at diagnosis, menopausal status, tumor size, nodal status, grade and systemic adjuvant therapy by multivariate Cox proportional hazards models. All P values were two-sided. Statistical analyses were performed using SPSS Statistics 21.0. P\<0.05 was considered significant.

Results {#sec1-3}
=======

Patients and follow up {#sec2-1}
----------------------

The study included 115 women with TNBC, 34 (28.7%) of whom were a normal weight (BMI \<25 kg/m^2^) and 82 (71.3%) of whom were overweight (BMI ≥25 kg/m^2^)

The normal weight group's median age was 47.1 years (range: 29--65 years). The overweight group's median age was 45.6 years (range: 26--87 years)

The overweight group had a significantly higher proportion of larger tumours (\>3 cm; p=0.05) with vascular emboli (p=0.038) and included more premenopausal women (p\<0.001). BMI was not associated with tumour grade, lymph node status and age ([Table 1](#T1){ref-type="table"}).

###### 

Baseline Characteristics of Patients

  Characteristics     IMC \< 25   IMC ≥ 25    p
  ------------------- ----------- ----------- ----------
  Tumor size (cm)                             
   ≤ 3                8 (23.5)    34 (42)     0.05
   \> 3               26 (76.5)   47 (58)     
  Lymph node status                           
   N --               16 (47)     32 (39.5)   0.276
   N +                18 (53)     49 (60.5)   
  Tumor grade                                 
   I -- II            20 (58.8)   45 (55.5)   0.428
   III                14 (41.2)   36 (44.5)   
  Vascular emboli                             
   No                 26 (76.5)   48 (59.3)   0.038
   Yes                8 (23.5)    33 (40.7)   
  Menopausal status                           
   Pre-               12 (35.3)   73 (90.2)   \< 0.001
   Post-              22 (64.7)   8 (9.8)     
  Age (years)                                 
  ≤ 40                11 (32.3)   27 (33.3)   0.586
  \> 40               23 (67.7)   54 (66.7)   

Mortality and disease progression {#sec2-2}
---------------------------------

Rates of overall mortality and disease progression at 5 years were 37.4% and 69.6%, respectively.

The normal weight group's rates of overall mortality and disease progression at 5 years were 41.9% and 61.3%, respectively. The overweight group's rates of overall mortality and disease progression at 5 years were 66.7% and 81.6%, respectively.

After adjusting for clinico-pathological variables and menopausal status, overweight BMI was associated with a worse overall survival OS (p=0,002) and disease-free survival DFS (p=0,002) than underweight BMI in patients with TNBC ([Figure 1](#F1){ref-type="fig"}).
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In multivariable analysis, overweight was significantly with OS (hazard ratio \[HR\] for mortality 2.903, 95% CI: 1.551- 5.432, p=0.001, [Table 3](#T2 T3){ref-type="table"}) and DFS (HR for progression 1.899, 95% CI: 1.05- 3.433, p=0.034, [Table 2](#T2){ref-type="table"}) after adjustment for clinicopathologic risk factors.

###### 

Univariate and Multivariate DFS Analysis of BMI in TNBC Patients According to Menopausal Status

  Menopausal status / BMI   Univariate p   Multivariate p   HR   95% CI
  ------------------------- -------------- ---------------- ---- --------
  Total                     0.002          0.034                 
   BMI ≤ 25                 1              \-                    
   BMI \>25                 1.899          1.05 -- 3.433         
  Premenopausal patients    0.05           0.016                 
   BMI ≤ 25                 1              \-                    
   BMI \>25                 3.242          1.249 -- 8.412        
  Postmenopausal patients   0.642          0.736                 
   BMI ≤ 25                 1              \-                    
   BMI \>25                 1.035          0.276 -- 6.172        

###### 

Univariate and Multivariate OS Analysis of BMI in TNBC Patients According to Menopausal Status

  Menopausal status / BMI   Univariate p   Multivariate p   HR   95% CI
  ------------------------- -------------- ---------------- ---- --------
  Total                     0.002          0.001                 
   BMI ≤ 25                 1              \-                    
   BMI \>25                 2.903          1.551-5.432           
  Premenopausal patients    0.019          0.011                 
   BMI ≤ 25                 1              \-                    
   BMI \>25                 2.752          1.267-5.978           
  Postmenopausal patients   0.036          0.648                 
   BMI ≤ 25                 1              \-                    
   BMI \>25                 1.345          0.375-4.831           

In stratification analysis, overweight was an independent prognostic factor for DFS (HR: 3.242, 95% CI: 1.249- 8.412, p=0.016, [Table 2](#T2){ref-type="table"}) and OS (HR: 2.752, 95% CI: 1.267- 5.978, p=0.011, [Table 3](#T3){ref-type="table"}).

Among postmenopausal women, BMI did not predict for DFS (HR: 1.345, 95% CI: 0.375--4.831, P = 0.648, [Table 2](#T2){ref-type="table"}) or OS (HR: 1.305, 95% CI: 0.276--6.172, p = 0.736, [Table 3](#T3){ref-type="table"}).

Discussion {#sec1-4}
==========

Patients with this breast cancer phenotype tend to have a worse clinical outcome partly as a result of lacking a therapeutic target. Consequently, establishing a relation between modifiable factors that may portend an adverse outcome potentially may be beneficial to these patients (Ademuyiwa et al., 2011).

A number of studies (Dal Maso et al.,2008; Kroenke et al., 2005; Loi et al., 2005; Nichols et al, 2009) have evaluated the adverse prognostic effect of general obesity before breast cancer diagnosis or at the time of or shortly after a diagnosis of breast cancer, but very few studies have focused on BMI's prognostic role in specially TNBC, the results of which vary considerably (Tao et al, 2006; Majed et at, 2008; Dawood et al, 2008).

In the current study, we demonstrated that overweight has a negative influence on DFS and OS only in premenopausal patients with TNBC but not in postmenopausal ones. Our results agreed with several reports in the literature, which showed that increasing BMI is related to a poor outcomes and short survivorship.

In a large study that involved 8,872 women, Fontanella et al demonstrated that mean DFS and OS were shorter in obese and very obese compared with normal weight patients in TNBC after a median follow up of 42.7 months (Fontanella et al., 2015). In a single center study of 818 patients with TNBC, obesity was associated with worse DFS and OS for premenopausal patients with TNBC at a median follow-up of 29 months (Turkoz et al., 2013). Pajares et al., (2013) performed a retrospective analysis including 5,683 operable BC patients enrolled in four randomized clinical trials (GEICAM/9906, GEICAM/9805, GEICAM/2003-02, and BCIRG 001) to assess the prognostic effect of body mass index (BMI) on disease recurrence, breast cancer mortality (BCM), and overall mortality (OM). As a result, Severely obese patients present a worse prognosis regarding recurrence, BCM, and OM than patients with BMI \< 25. The magnitude of the harmful effect of BMI on survival-related outcomes was similar across subtypes including TNBC. Shuang Hao et al investigated the prognostic effects of body mass index (BMI) on clinical outcomes in 1106 patients with TNBC. They identified Overweight as an independent prognostic factor of OS in all women with TNBC, and menopause status as mitigating factor (Hao et al., 2015). Premenoposaul women who are overwheight with TNBC are at a greater risk of poor prognosis than normal weight ones. On the other side, no significant relationship between obesity and outcomes in patients with TNBC after controlling for clinically significant factors was found either by Tait et al., (2014) or Ademuyiwa et al (Ademuyiwa et al., 2011). This is possibly because TNBC patients tend to receive cytotoxic chemotherapy which may neutralize potential detrimental effects of a higher BMI (Hao et al., 2015).

There are several hypotheses on the mechanisms that link increasing BMI to TNBC prognosis (Rose et al., 2009; Verreault et al.,1989; Foluso et al., 2011). Such as obesity associated comorbidities that interfere with optimal treatment (Hao et al., 2015). Metabolic syndrome, presents increased levels of insulin and insulin-like growth factor, hormones with potent mitogenic activity toward epithelial cells (Nelson et al., 2013; Renehan et al., 2006; Yu et al., 2000). Also paracrine secretion of interleukin-6 and tumor necrosis factor-alpha and the establishment of a pro-inflammatory micro-environment can induce the development of malignant phenotypes that are independent of hormonal secretion (Howe et al., 2013). Alternatively, the detrimental effect of obesity on TNBC prognosis might be linked to sub-therapeutic treatment. Drug dosing has traditionally been based on a patient's estimated body surface area (BSA) in adults (Chen et al., 2016). It's suggested elsewhere that the adipokines, which include leptin and vascular endothelial growth factor and heparin-binding epidermal growth factor- like growth factor, exert a stimulatory effect on ER-negative breast cancers, where estrogen action is not a factor, by hormonal, paracrine, and autocrine mechanisms (Zheng et al., 2013). Ishikawa et al., (2004) found that high leptin and leptin receptor expression in breast cancer tissue was associated with distant metastases. And Liu et al., (2011)reported that serum leptin concentrations were higher in patients with high-grade tumors and that a polymorphism in the leptin receptor gene at codon 109 (LEPRO-109RR genotype) was more frequent in patients who were overweight and those with triple-negative cancers. Leptin implicate stimulatory effects on breast cancer cell proliferation and invasion, but also possesses angiogenic activity (Niu et al., 2013).

It seems to be the first study to examine the relationships between obesity and TNBC survival outcomes in Moroccan patients, to our knowledge. Our study established a relationship between overweight and TNBC which is beneficial for this aggressive subtype of breast cancer. These results will be taken into account in the programs of prevention and also in the medical management by using intensified treatments in patients with overweight. However, there were some potential limitations in our study. Firstly, due to the relatively proportion of underweight and obese patients, classification was measured in a binary scale. This classification did not allow to clearly distinguish between women who were obese and those who were overweight. Secondly, the retrospective nature of the study design and its relatively small sample size.

In conclusion, this retrospective cohort analysis showed that overweight BMI was an independent prognostic factor for OS and DFS at 5 years in women with TNBC. Our analysis indicated that menopausal status may be a mitigating factor, with overweight premenopausal women at greater risk of death and progression than women with a normal weight. Clearly, the relationships between outcome and obesity in triple-negative breast cancer are an important topic for further study. Once validated, these results could be considered in the clinical management of breast cancer and in the development of targeted preventive programs.
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